Another top IPO: Adarx’s $446M to advance clinical siRNA assets
Why now
Thesis: Adarx IPO tests appetite for siRNA drugmakers
Catalyst to watch: Post-IPO share performance and trial updates
Main risk: Clinical failures could sour IPO demand
Why it matters
Another sizable biotech IPO indicates selective investor appetite for clinical-stage siRNA assets.
Sources
- googlenews · news.google.com · 2026-09-25 20:29 UTC
- googlenews · news.google.com · 2026-09-25 20:29 UTC